ClinicalTrials.gg
CompletedNCT02373072Updated Sep 22, 2023

A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of PF-06649751 in Subjects With Idiopathic Parkinson's Disease

A Phase 1 interventional study of PF-06649751 and Trimethobenzamide Hydrochloride in Idiopathic Parkinson Disease, sponsored by Pfizer. Completed at 8 sites in 2 countries. Open to participants aged 30 Years to 85 Years. Per ClinicalTrials.gov, last updated 2023-09-22.

Sponsored by Pfizer · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
18
Allocation
Randomized
Ages
30 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 11 studies testing tavapadon in Parkinson Disease — none open to participants now, none under way, none of them phase 3. tavapadon · Parkinson Disease.

Enrollment
10th of 11
18 · median 57
Started
2015
the only one that year
Phase 1
5 of 11
none open now
Registered
2nd of 11
by date
Lead sponsor
4 of 11
Pfizer

Among the 11 studies testing tavapadon in Parkinson Disease, this one is the 10th largest by enrollment, is the only one that started in 2015, is one of 5 in phase 1, and was the 2nd registered.

Parkinson Disease

4,578 studies on the registry are indexed under Parkinson Disease; 1,085 are open to participants now.

Browse Parkinson Disease studies →

Open to participants now

None of the 11 studies testing tavapadon in Parkinson Disease is open now. The open studies under Parkinson Disease, anywhere →

About tavapadon

tavapadon: first FDA approval 2026 (JUVMO). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 748 Parkinson Disease studies recruiting now, 311 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.

This study: 30 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 11 studies testing tavapadon in Parkinson Disease as a file.
02

Study summary

This is a study with two sequential cohorts, each with three treatment periods. Single doses of PF-06649751 will be tested in this study, starting at a low dose and escalating to a dose projected to be under the current limits for drug concentration. Each cohort will aim to achieve approximately 9 completers. Primary endpoint is safety and tolerability, secondary endpoint is MDS-UPDRS part III.

03

Conditions studied

  • Idiopathic Parkinson Disease

Keywords

  • Pakinson's Disease, Movement Disorders
04

Who can participate

Ages eligible
30 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • L-DOPA-responsiveness
  • Hoehn \& Yahr Stage II-III inclusive
  • Experiencing motor fluctuations
  • Stable daily dose of L-DOPA of at least 300 mg
  • Females on non- and male subjects

Exclusion criteria

Exclusion Criteria:

  • History of troublesome dyskinesias
  • History of surgical intervention for Parkinson's disease
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
18 participants (actual)

Study arms

  • Experimental
    Cohort 1

    Three single doses over three periods. For each of the three periods, subjects will be crossed-over from placebo or PF-06649751. Each PF-06649751 dose is separated by at least one week.

    Drug: PF-06649751 · Drug: Trimethobenzamide Hydrochloride · Drug: Placebo

  • Experimental
    Cohort 2

    Three single doses over three periods. For each of the three periods, subjects will be crossed-over from placebo or PF-06649751. Each PF-06649751 dose is separated by at least one week.

    Drug: PF-06649751 · Drug: Trimethobenzamide Hydrochloride · Drug: Placebo

Interventions

  • Subjects completing all three treatment periods will be administered two doses. Doses: 0.75mg, 1.5mg, 3mg, 6mg, 9mg. Tablets in the form of 0.25mg or 1 mg.

  • DrugTrimethobenzamide Hydrochloride

    300mg TID, Capsules. Optional in both Cohorts.

  • DrugPlacebo

    Subjects completing all three treatment periods will be receiving placebo once.

06

What researchers measure

Primary outcomes

  1. Number and proportion of subjects with Adverse Events (AEs)

    Time frame: Day 1 through 61

  2. Number of participants with vital signs data that meet criteria of potential clinical concern

    Time frame: Day 1 through 61

  3. Number of participants with ECG data that meet criteria of potential clinical concern

    Time frame: Day 1 through 61

  4. Number of participants with abnormal clinically significant laboratory measurements

    Time frame: Day 1 through 61

  5. C-SSRS (suicidality assessment)

    Time frame: Day 1 through 61

Secondary outcomes

  1. MDS-UPDRS part III

    MDS - Unified Parkinson's Disease Rating Scale Part III

    Time frame: Day 1, Periods 1-3

07

Study locations

8 sites
  • Collaborative Neuroscience Network, LLC.
    Long Beach, California 90806, United States
  • MD Clinical
    Hallandale Beach, Florida 33009, United States
  • Atlanta Center for Medical Research
    Atlanta, Georgia 30331, United States
  • SNBL Clinical Pharmacology Center, Inc.
    Baltimore, Maryland 21201, United States
  • Parkinson's Movement Disorder Center of Maryland
    Elkridge, Maryland 21075, United States
  • Neurology Consultants of Dallas, PA
    Dallas, Texas 75231, United States
  • Walnut Hill Medical Center
    Dallas, Texas 75231, United States
  • Pfizer Clinical Research Unit
    Brussels, B-1070, Belgium
08

References and documents

Publications

  • Sohur US, Gray DL, Duvvuri S, Zhang Y, Thayer K, Feng G. Phase 1 Parkinson's Disease Studies Show the Dopamine D1/D5 Agonist PF-06649751 is Safe and Well Tolerated. Neurol Ther. 2018 Dec;7(2):307-319. doi: 10.1007/s40120-018-0114-z. Epub 2018 Oct 25. PubMed 30361858 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2015, a primary completion of Feb 2016 and a completion of Mar 2016. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 20, 2015
First posted
Feb 26, 2015
Start
Mar 2015
Primary completionActual
Feb 2016
CompletionActual
Mar 2016
Last update
Sep 22, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 22, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02373072
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Feb 26, 2015
Start date
Mar 2015
Primary completion
Feb 2016
Completion
Mar 2016
Last update
Sep 22, 2023

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tavapadon

Start the discussion